arrow
N

Niklas Gebauer

university hospital schleswig-holstein campus lübeck
H指数:18
被引数:1,201

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic Value of Regnase-1 in High-Grade Soft Tissue Sarcoma: Favourable in UPS, Yet Inverted in Adjuvantly Irradiated Patients

Regnase-1在高级别软组织肉瘤中的预后价值:在UPS中良好,但在辅助放疗患者中逆转

Cancers
IF4.4
2026-04-290
OA
Non-ICANS neurotoxicities CD19-directed CAR T-cell therapy and the emergence of movement and neurocognitive treatment-emergent adverse events: a case report

非ICANS神经毒性与CD19定向CAR T细胞疗法及运动和神经认知治疗相关不良事件的 emergence:一个病例报告

2026-02-160
OAAI
Molecular profiling of primary renal diffuse large B-cell lymphoma unravels a proclivity for immune-privileged tropism

原发性肾弥漫大B细胞淋巴瘤的分子分型揭示了其对免疫特惠部位的嗜性

2025-05-260
OA
Molecular profiling of primary renal marginal zone lymphoma reveals overlapping features with extranodal marginal zone lymphoma

原发性肾边缘区淋巴瘤的分子特征分析揭示其与结外边缘区淋巴瘤具有重叠特征

2025-05-130
OA
Ruxolitinib mediated paradoxical JAK2 hyperphosphorylation is due to the protection of activation loop tyrosines from phosphatases

鲁索利替尼介导的矛盾性JAK2过度磷酸化是由于保护了激活环酪氨酸免受磷酸酶的影响。

LEUKEMIA
IF13.4
2025-04-230
OA
Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma

双特异性抗体疗法在复发/难治性大B细胞淋巴瘤中CAR T细胞治疗失败后的疗效

2025-04-190
OA
Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma

CAR-T失败时间是对复发/难治性大B细胞淋巴瘤双特异性抗体疗法结局的强预测因子

BLOOD
IF23.1
2024-11-051
PRE
Case report: Tenosynovial giant cell tumor
2024-09-260
OAAI
Genome-wide DNA methylation-analysis of blastic plasmacytoid dendritic cell neoplasm identifies distinct molecular features
LEUKEMIA
IF13.4
2024-04-103
OAAI
Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations

与治疗考虑因素密切相互作用的母细胞性浆细胞样树突状细胞肿瘤 (BPDCN) 的诊断管理

2024-01-093
OAAI